Jeremy Bender, Day One Biopharmaceuticals CEO

With pan-RAF drug from Take­da, Day One un­veils its first pe­di­atric brain can­cer da­ta. And the mar­ket loves it

Day One Bio­phar­ma­ceu­ti­cals has gath­ered the first cut of Phase II da­ta on its quest to repo­si­tion a Take­da drug as a treat­ment for pe­di­atric can­cer, and in­vestors are ev­i­dent­ly thrilled.

With an over­all re­sponse rate of 64% among the first 25 pa­tients who have a type of brain tu­mor called re­cur­rent or pro­gres­sive low-grade glioma (pLGG), Day One said late Sun­day the re­sults bode well for the rest of the FIRE­FLY-1 study, which fea­tures a reg­is­tra­tional co­hort out of three arms. That co­hort is ful­ly en­rolled and ex­pect­ed to get to a read­out in 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.